Zacks Investment Research downgraded shares of ONCOMED PHARMA (OMED) from NEUTRAL to UNDERPERFORM on March 25, 2014, with a target price of $31.60.
OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ONCOMED PHARMA (OMED),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment